ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics

Original Article - click here to go to article.

The Pharmacogenomics Journal advance online publication 17 November 2009; doi: 10.1038/tpj.2009.55

Y-R Liu^1,2,11, E-W Loh^1,11, T-H Lan^1,3,4, S-F Chen⁵, Y-H Yu⁶, Y-H Chang^1,7, C-J Huang⁸, T-M Hu⁹, K-M Lin¹, Y-T Yao² and H-J Chiu¹⁰

1. Division of Mental Health and Addiction Medicine, Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan
2. Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan
3. Faculty of Medicine, National Yang Ming University, Taipei, Taiwan
4. Department of Psychiatry, Taichung Veterans General Hospital, Taichung, Taiwan
5. Institute of Food Science and Technology, National Taiwan University, Taipei, Taiwan
6. Department of Life Sciences and Institute of Genome Sciences, National Yang Ming University, Taipei, Taiwan
7. Institute of Public Health and Department of Public Health, National Yang Ming University, Taipei, Taiwan
8. Department of Industrial Engineering and Engineering Management, College of Engineering, National Tsing-Hua University, HsinChu, Taiwan
9. Department of Psychiatry, Yu-Li Veterans Hospital, Hualian County, Taiwan
10. Jianan Mental Hospital, Tainan County, Taiwan

Correspondence: Dr H-J Chiu, Department of Health, Jianan Mental Hospital, #80, Lane 870, Jhung-Shan Road, Rende Township, Tainan 717, Taiwan. E-mail: chiu8@mail2000.com.tw

¹¹These authors contributed equally to this study.

Received 28 April 2009; Revised 28 July 2009; Accepted 23 September 2009; Published online 17 November 2009.

Abstract

Noradrenaline and adrenaline are neurotransmitters of the sympathetic nervous system that interact with various adrenergic receptor (ADR) subtypes, and this regulates the basal metabolic rate, thermogenesis and efficiency of energy utilization. We examined a possible role of the gene coding for ADRA1A receptor in weight gain in schizophrenia subjects exposed to antipsychotics. A total of 401 schizophrenia in-patients treated with antipsychotics for >2 years were recruited and a final 394 DNA samples were genotyped. Their body mass indexes (BMIs) were recorded for 12 months and parameterized to be correlated in regression. Among the 58 single-nucleotide polymorphisms (SNPs) genotyped, 44 valid SNPs, which had minor allele frequency 0.03, were analyzed in statistics. Linear regression model with age, gender, diabetes, use of typical antipsychotics and use of atypical antipsychotics as covariates, with or without gender interaction, showed evidence of associations between the ADRA1A gene and BMI. Most of the SNPs associated with BMI are located in the promoter and intron regions, and being female appeared to enhance the gene effect. Our study suggests that the ADRA1A gene is involved in weight gain among schizophrenia patients treated with antipsychotics. Further molecular dissection of the ADRA1A gene warrants better understanding on weight gain mechanisms in schizophrenia.

The modulating effect of the androgen receptor on craving in alcohol withdrawal of men is partially mediated by leptin

For article, click here.

Original Article

The Pharmacogenomics Journal advance online publication 3 November 2009; doi: 10.1038/tpj.2009.56

B Lenz 1,
H Frieling 1,2,
C Jacob 1,
A Heberlein 1,2,
J Kornhuber 1,
S Bleich 1,2 and
T Hillemacher 1,2

1. Department of Psychiatry and Psychotherapy, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany
2. Department of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany

Correspondence: Dr B Lenz, Department of Psychiatry and Psychotherapy, Friedrich-Alexander-University of Erlangen-Nuremberg, Schwabachanlage 6-10, D-91054 Erlangen, Germany. E-mail: bernd.lenz@uk-erlangen.de

Received 3 August 2009; Revised 2 October 2009; Accepted 6 October 2009; Published online 3 November 2009.
Abstract

We reported recently that a functional relevant CAG trinucleotide repeat of the androgen receptor influences craving of men in alcohol withdrawal. It is known to modulate serum concentrations of leptin, which affects hypothalamic appetite regulation. Its plasma levels are elevated during chronic alcohol consumption, normalize within periods of abstinence and are associated with craving. The aim of this study was to further elucidate the role of leptin in mediating the effects of the mentioned polymorphism on craving in men undergoing alcohol withdrawal. We included 110 male in-patients who were admitted for detoxification treatment. Each one had an established diagnosis of alcohol dependence according to the DSM-IV. Our results show on the one hand negative associations between the number of CAG repeats and (i) leptin serum levels (P<0.01)>P<0.05),>P<0.001).>r=-0.144) accounting for 60% and indirect, leptin-mediated effects (r=-0.096) accounting for 40% of the total effect. Dysregulation of sexual hormones influences human metabolism and seems to affect leptin homeostasis. This report suggests that the investigated polymorphism mediates its effect on craving of men in alcohol withdrawal mostly through the regulation of leptin. Nevertheless future studies are needed to further explore the functionality of the androgen receptor gene in terms of craving.

Featured Review: The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy

Click here for article.

The Pharmacogenomics Journal advance online publication 3 November 2009; doi: 10.1038/tpj.2009.54

S P R Romaine¹, K M Bailey¹, A S Hall² and A J Balmforth¹

1. Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, UK
2. Multidisciplinary Cardiovascular Research Centre (MCRC), Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, UK

Correspondence: SPR Romaine, Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics, Health and Therapeutics, The LIGHT Laboratories, University of Leeds, Leeds LS2 9JT, UK. E-mail: S.Romaine04@leeds.ac.uk

Received 23 April 2009; Revised 15 September 2009; Accepted 28 September 2009; Published online 3 November 2009.

Abstract

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are well established in the treatment of hypercholesterolaemia and the prevention of coronary artery disease. Despite this, there is wide inter-individual variability in response to statin therapy, in terms of both lipid-lowering and adverse drug reactions. The major site of statin action is within hepatocytes and recent interest has focussed on genetic variation in hepatic influx and efflux transporters for their potential to explain these differences. In this review we explore current literature regarding the pharmacokinetic and pharmacodynamic influence of the common c.388A>G and c.521T>C single-nucleotide polymorphisms (SNPs) within the solute carrier organic anion transporter 1B1 (SLCO1B1) gene, encoding the organic anion transporter polypeptide 1B1 (OATP1B1) influx transporter. We discuss their potential to predict the efficacy of statin therapy and the likelihood that patients will experience adverse effects.

Very interesting new article on pharmacogenomics

By Jeffrey Perkel.

Click here to read it.

Risk of ischemic vascular disease in 52 000 individuals

For the article, click here.

Original Article

The Pharmacogenomics Journal advance online publication 4 August 2009; doi: 10.1038/tpj.2009.34

Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52 000 individuals

D Kaur-Knudsen1,2,4, S E Bojesen1,2,3,4 and B G Nordestgaard1,2,3,4

1. Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark
2. The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark
3. The Copenhagen City Heart Study, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen, Denmark
4. Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

Correspondence: Professor BG Nordestgaard, Department of Clinical Biochemistry, 54M1, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. E-mail: brno@heh.regionh.dk

Received 3 April 2009; Accepted 25 June 2009; Published online 4 August 2009.
Top of page
Abstract

Cytochrome P450 2C9 (CYP2C9) enzymes metabolize warfarin and arachidonic acid. We hypothesized that the CYP2C9*2 (rs.1799853) and CYP2C9*3 (rs.1057910) polymorphisms with decreased enzyme activity affect risk of subclinical atherosclerosis (reduced ankle brachial index and increased C-reactive protein), ischemic vascular diseases (ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease and ischemic stroke) and death after an ischemic heart disease diagnosis. We genotyped the Copenhagen City Heart Study, a prospective study including 10 398 participants with 30–32 years of follow-up; the Copenhagen General Population Study, a cross-sectional study including 21 629 participants; and the Copenhagen Ischemic Heart Disease Study, a case–control study including 5082 cases and 14 904 controls. CYP2C9 carriers versus noncarriers did not associate with subclinical atherosclerosis. Furthermore, the odds/hazard ratios for ischemic vascular disease did not differ from 1.0 for CYP2C9 carriers versus noncarriers. Finally, we found no altered risk of early death after a diagnosis of ischemic heart disease. For all end points, we could exclude even minor changes in risk of disease with 90% power. In conclusion, in three independent studies totaling more than 52 000 individuals, we found no association between CYP2C9*2 and CYP2C9*3 polymorphisms and risk of subclinical atherosclerosis, ischemic vascular disease or death after ischemic heart disease.

Adrenomedullin gene (ADM) and response to paroxetine

For a link to the article, click here.

Original Article

The Pharmacogenomics Journal advance online publication 28 July 2009; doi: 10.1038/tpj.2009.33

Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine

D M Glubb 1, P C McHugh 1, X Deng 1, P R Joyce 2 and M A Kennedy 1

1 Gene Structure & Function Laboratory, Department of Pathology, University of Otago, Christchurch, New Zealand

2 Department of Psychological Medicine, University of Otago, Christchurch, New Zealand

Correspondence: Dr DM Glubb, Department of Pathology, Gene Structure & Function Laboratory, University of Otago, Christchurch P.O. Box 4345, Christchurch 8140, New Zealand. E-mail: dylan.glubb@otago.ac.nz

Received 17 February 2009; Revised 8 May 2009; Accepted 25 June 2009; Published online 28 July 2009.

Abstract

To identify genes that may be relevant to the molecular action of antidepressants, we investigated transcriptional changes induced by the selective serotonin reuptake inhibitor paroxetine in a serotonergic cell line. We examined gene expression changes after acute treatment with paroxetine and sought to validate microarray results by quantitative PCR (qPCR). Concordant transcriptional changes were confirmed for 14 genes by qPCR and five of these, including the adrenomedullin gene (Adm), either approached or reached statistical significance. Reporter gene assays showed that a SNP (rs11042725) in the upstream flanking region of ADMsignificantly altered expression. Association analysis demonstrated rs11042725 to be significantly associated with response to paroxetine (odds ratio=0.075, P<0.001)>ADM is involved with the therapeutic efficacy of paroxetine, which may have pharmacogenetic utility.

Transgenic primates as research tools: now a reality

To see the article, click here

Article

Nature 459, 523-527 (28 May 2009) | doi:10.1038/nature08090; Received 27 September 2008; Accepted 30 April 2009

Generation of transgenic non-human primates with germline transmission

Erika Sasaki¹, Hiroshi Suemizu¹, Akiko Shimada¹, Kisaburo Hanazawa², Ryo Oiwa¹, Michiko Kamioka¹, Ikuo Tomioka^1,3, Yusuke Sotomaru⁵, Reiko Hirakawa^1,3, Tomoo Eto¹, Seiji Shiozawa^1,4, Takuji Maeda^1,4, Mamoru Ito¹, Ryoji Ito¹, Chika Kito¹, Chie Yagihashi¹, Kenji Kawai¹, Hiroyuki Miyoshi⁶, Yoshikuni Tanioka¹, Norikazu Tamaoki¹, Sonoko Habu⁷, Hideyuki Okano⁴ & Tatsuji Nomura¹

1. Central Institute for Experimental Animals, 1430 Nogawa, Miyamae-ku, Kawasaki, Kanagawa 216-0001, Japan
2. Department of Urology, Juntendo University Nerima Hospital 3-1-10 Takanodai, Nerima-ku, Tokyo 177-8521, Japan
3. Center for Integrated Medical Research,
4. Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
5. Natural Science Centre for Basic Research and Development, Hiroshima University 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan
6. Subteam for Manipulation of Cell Fate, RIKEN BioResource Centre, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan
7. Department of Immunology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan

Correspondence to: Erika Sasaki¹Hideyuki Okano⁴ Correspondence and requests for materials should be addressed to E.S. (Email: esasaki@ciea.or.jp) or H.O. (Email: hidokano@sc.itc.keio.ac.jp).

Abstract

The common marmoset (Callithrix jacchus) is increasingly attractive for use as a non-human primate animal model in biomedical research. It has a relatively high reproduction rate for a primate, making it potentially suitable for transgenic modification. Although several attempts have been made to produce non-human transgenic primates, transgene expression in the somatic tissues of live infants has not been demonstrated by objective analyses such as polymerase chain reaction with reverse transcription or western blots. Here we show that the injection of a self-inactivating lentiviral vector in sucrose solution into marmoset embryos results in transgenic common marmosets that expressed the transgene in several organs. Notably, we achieved germline transmission of the transgene, and the transgenic offspring developed normally. The successful creation of transgenic marmosets provides a new animal model for human disease that has the great advantage of a close genetic relationship with humans. This model will be valuable to many fields of biomedical research.